Cell Genesys Confirms Publication of Scientific Paper on GVAX(R) Lung Cancer Vaccine

23-Feb-2004

Cell Genesys, Inc. confirmed that a press release issued by Baylor University concerned data from the initial Phase 1/2 clinical trial of Cell Genesys' GVAX® lung cancer vaccine trial. The data, which were published in the February 18, 2004 issue of the Journal of the National Cancer Institute, were previously presented in December 2002 at the International Conference on gene therapy of Cancer. Cell Genesys is currently conducting a Phase 2 trial of GVAX® lung cancer vaccine to confirm the previous findings using a new semiautomated closed system to produce the vaccine. A second Phase 2 trial, which is expected to be sponsored and partially funded by the Southwest Oncology Group (SWOG), a cooperative clinical trials group of the National Cancer Institute (NCI), will focus on patients with the bronchoalveolar carcinoma (BAC) subtype of non small-cell lung cancer and is expected to be initiated in the second quarter of 2004. Cell Genesys is focused on the research, development and commercialization of biological therapies for patients with cancer. The company is pursuing three cancer product platforms-GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies. Clinical trials of GVAX® vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Clinical programs of oncolytic virus therapies include CG7870 for prostate cancer. Preclinical studies are in progress for additional GVAX® cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies for multiple types of cancer. Cell Genesys' majority-owned subsidiary, Ceregene, Inc., is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold an equity interest in its former subsidiary, Abgenix, Inc., an antibody products company. Cell Genesys is headquartered in South San Francisco, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.

View topic world

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.